{
    "clinical_study": {
        "@rank": "75397", 
        "arm_group": [
            {
                "arm_group_label": "Burlulipase", 
                "arm_group_type": "Experimental", 
                "description": "Burlulipase orally, per meal"
            }, 
            {
                "arm_group_label": "Placebo (Caramel in sterile water)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo orally, per meal"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this Randomized, Double-blind, Multicenter, Two-period Crossover Study is to\n      Assess the Efficacy and Tolerability of Burlulipase (NM-BL) in Patients with Exocrine\n      Pancreatic Insufficiency due to Cystic Fibrosis"
        }, 
        "brief_title": "Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pancreatic Insufficiency", 
            "Cystic Fibrosis", 
            "Digestive System Diseases", 
            "Lung Diseases", 
            "Respiratory Tract Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Digestive System Diseases", 
                "Gastrointestinal Diseases", 
                "Fibrosis", 
                "Lung Diseases", 
                "Exocrine Pancreatic Insufficiency", 
                "Respiratory Tract Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients aged \u226512 years from the date of informed consent\n\n          -  Confirmed diagnosis of CF at screening\n\n          -  Confirmed EPI by historical (within past 12 months) CFA <70% without use of PERTs or\n             current fecal elastase <50 \u00b5g/g stool at screening\n\n          -  Currently receiving PERT with a commercially available pancreatic enzyme\n\n          -  Currently on stable treatment with proton pump inhibitors or H2 receptor antagonists\n\n          -  Clinically stable condition without evidence of acute respiratory disease or any\n             other acute condition\n\n        Exclusion Criteria:\n\n          -  History of fibrosing colonopathy\n\n          -  History of significant bowel resection, in the opinion of the investigator, or solid\n             organ transplant\n\n          -  History of being refractory to pancreatic enzyme replacement\n\n          -  Current diagnosis or history of distal intestinal obstruction syndrome\n\n          -  Current diagnosis of small intestinal bacterial overgrowth, ileus or acute abdomen\n\n          -  A body mass index percentile <10%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710644", 
            "org_study_id": "NM-BL-101", 
            "secondary_id": "207862"
        }, 
        "intervention": [
            {
                "arm_group_label": "Burlulipase", 
                "description": "Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days", 
                "intervention_name": "Burlulipase", 
                "intervention_type": "Drug", 
                "other_name": "NM-BL"
            }, 
            {
                "arm_group_label": "Placebo (Caramel in sterile water)", 
                "description": "Placebo will be taken with meals and snacks for 5 to 7 days", 
                "intervention_name": "Placebo (Caramel in sterile water)", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Elizabeth.Deluca@nemours.org", 
                    "last_name": "Betty DeLuca", 
                    "phone": "904-697-3804"
                }, 
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32207"
                    }, 
                    "name": "Nemours Children's Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "okan.elidemir@nemours.org", 
                    "last_name": "Okan Elidemir", 
                    "phone": "850-473-4784"
                }, 
                "facility": {
                    "address": {
                        "city": "Pensacola", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32504"
                    }, 
                    "name": "Nemours Children's Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mary-teresi@uiowa.edu", 
                    "last_name": "Mary Teresi", 
                    "phone": "319-384-7546"
                }, 
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "The University of Iowa"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Sheri.Miller@via-christi.org", 
                    "last_name": "Sheri Miller", 
                    "phone": "316-268-6028"
                }, 
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67214"
                    }, 
                    "name": "Via Cristi Hospitals Wichita, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "donna.buckley@cchmc.org", 
                    "last_name": "Donna Buckley", 
                    "phone": "513-636-8549"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "Cincinnati Children's Hospital Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "david.weaver@uhhospitals.org", 
                    "last_name": "David Weaver", 
                    "phone": "216-983-0469"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "University Hospitals Case Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bartosiks@childrensdayton.org", 
                    "last_name": "Sandy Bartosik", 
                    "phone": "937-641-4004"
                }, 
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45404"
                    }, 
                    "name": "The Children's Medical Center of Dayton"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dkitch@hmc.psu.edu", 
                    "last_name": "Diane Kitch", 
                    "phone": "717-531-5646"
                }, 
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033"
                    }, 
                    "name": "Penn State Milton S. Hershey Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "scollins@hsc.wvu.edu", 
                    "last_name": "Sue Collins", 
                    "phone": "304-293-7348"
                }, 
                "facility": {
                    "address": {
                        "city": "Morgantown", 
                        "country": "United States", 
                        "state": "West Virginia", 
                        "zip": "26506"
                    }, 
                    "name": "West Virginia University Research Corporation"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis", 
        "other_outcome": {
            "description": "Comparison gastrointestinal parameters, recorded by the patient/carer in the Symptom Questionnaire each day during the Treatment Periods", 
            "measure": "Symptomatology / Symptom Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "overall_contact": {
            "email": "cornelia.breuer@nordmark-pharma.de", 
            "last_name": "Cornelia Breuer", 
            "phone": "+49-4122-712-0"
        }, 
        "overall_official": [
            {
                "affiliation": "Nordmark Arzneimittel GmbH & Co. KG", 
                "last_name": "Kristin Forssmann, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Children's Hospital Medical Center, Cincinnati", 
                "last_name": "James E. Heubi, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To evaluate the efficacy of NM-BL compared to placebo in patients with Exocrine Pancreatic Insufficiency    (EPI) due to CF, where the primary variable is coefficient of fat absorption (CFA%)", 
            "safety_issue": "No", 
            "time_frame": "72 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710644"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To evaluate the efficacy of NM-BL compared to placebo in patients with Exocrine Pancreatic Insufficiency (EPI)due to CF, where the primary variable is coefficient of nitrogen absorption (CNA%)", 
            "safety_issue": "No", 
            "time_frame": "72 hrs"
        }, 
        "source": "Nordmark Arzneimittel GmbH & Co. KG", 
        "sponsors": {
            "collaborator": {
                "agency": "Parexel", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Nordmark Arzneimittel GmbH & Co. KG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}